for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cytosorbents Corp

CTSO.OQ

Latest Trade

4.52USD

Change

-0.02(-0.44%)

Volume

28,738

Today's Range

4.44

 - 

4.63

52 Week Range

3.68

 - 

12.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Cytosorbents Reports Q2 Revenue $6.233 Million

Aug 6 (Reuters) - Cytosorbents Corp <CTSO.O>::CYTOSORBENTS REPORTS RECORD SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 REVENUE $6.233 MILLION VERSUS REFINITIV IBES ESTIMATE OF $6.2 MILLION.EXPECT Q3 2019 PRODUCT SALES WILL EXCEED SALES REPORTED IN Q3 OF 2018.EXPECT THAT SECOND HALF 2019 PRODUCT SALES WILL EXCEED FIRST HALF 2019 PRODUCT SALES.QTRLY LOSS PER SHARE $0.11.

Cytosorbents Qtrly Loss Per Share $0.15

May 7 (Reuters) - Cytosorbents Corp <CTSO.O>::CYTOSORBENTS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES SECOND QUARTER 2019 GUIDANCE.Q1 REVENUE $5.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $6.2 MILLION.BELIEVE THAT WE HAVE SUFFICIENT CASH TO FUND OUR OPERATIONS INTO 2020.QTRLY LOSS PER SHARE $0.15.CONTINUE TO FORECAST STRONG REVENUE GROWTH FOR ALL OF 2019, DESPITE A SLOW START IN Q1.Q2 2019 PRODUCT SALES ARE EXPECTED TO RETURN TO OUR HISTORICAL GROWTH TRAJECTORY.CYTOSORBENTS - Q2 PRODUCT SALES ANTICIPATED TO BE HIGHEST QUARTERLY PRODUCT SALES REPORTED IN CO'S HISTORY.

Israel Approves Cytosorb Registration

March 25 (Reuters) - Cytosorbents Corp <CTSO.O>::ISRAEL APPROVES CYTOSORB REGISTRATION, CYTOSORBENTS ANNOUNCES GAD MEDICAL AS DISTRIBUTOR.CYTOSORBENTS CORP - NEW ISRAELI DISTRIBUTOR, GAD MEDICAL WILL HAVE EXCLUSIVE RIGHTS TO SELL CYTOSORB FOR ALL APPLICATIONS IN ISRAEL.

Cytosorbents Achieves Record Revenue And Product Sales Growth In 2018

March 7 (Reuters) - Cytosorbents Corp <CTSO.O>::CYTOSORBENTS ACHIEVES RECORD REVENUE AND PRODUCT SALES GROWTH IN 2018.CYTOSORBENTS CORP - EXPECT Q1 2019 PRODUCT SALES TO EXCEED SALES REPORTED IN Q1 OF 2018.

Cytosorbents Says Expanded Direct Sales Of Cytosorb For All Applications To Poland And Netherlands

March 5 (Reuters) - Cytosorbents Corp <CTSO.O>::CYTOSORBENTS - EXPANDED DIRECT SALES OF CYTOSORB FOR ALL APPLICATIONS TO POLAND, NETHERLANDS, & FOR CRITICAL CARE APPLICATIONS IN SWEDEN, DENMARK, NORWAY.CYTOSORBENTS CORP - COMPANY ESTABLISHED CYTOSORBENTS POLAND SP. Z.O.O., A WHOLLY-OWNED SUBSIDIARY OF CYTOSORBENTS EUROPE GMBH.

Cytosorbents Announces Expansion Of Cytosorb Partnership With Fresenius Medical Care

Jan 22 (Reuters) - Cytosorbents Corp <CTSO.O>::CYTOSORBENTS ANNOUNCES EXPANSION OF CYTOSORB® PARTNERSHIP WITH FRESENIUS MEDICAL CARE.CYTOSORBENTS - HAS EXPANDED PARTNERSHIP WITH FRESENIUS MEDICAL CARE TO KOREA & MEXICO.CYTOSORBENTS CORP - FINANCIAL TERMS OF AGREEMENT HAVE NOT BEEN DISCLOSED.CYTOSORBENTS - UNDER TERMS, FRESENIUS MEDICAL HAS EXCLUSIVE RIGHTS TO DISTRIBUTE CYTOSORB FOR ACUTE CARE, OTHER HOSPITAL APPLICATIONS IN KOREA & MEXICO.CYTOSORBENTS - COMMERCIAL SALES OF CYTOSORB EXPECTED TO START AFTER SECURING MARKET REGISTRATION CLEARANCE FROM KOREAN & MEXICAN HEALTH AUTHORITIES.

Cytosorbents Sees FY 2018 Revenue Of About $22.3 Mln

Jan 7 (Reuters) - Cytosorbents Corp <CTSO.O>::CYTOSORBENTS ISSUES STOCKHOLDER LETTER WITH PRELIMINARY 2018 FINANCIAL RESULTS.SEES FY 2018 REVENUE AT LEAST $22.3 MILLION.SEES Q4 2018 PRODUCT SALES OF APPROXIMATELY $5.4 MILLION.Q4 REVENUE VIEW $6.3 MILLION -- REFINITIV IBES DATA.FY2018 REVENUE VIEW $22.7 MILLION -- REFINITIV IBES DATA.

Cytosorbents Reports Third Quarter 2018 Financial Results

Nov 6 (Reuters) - Cytosorbents Corp <CTSO.O>::CYTOSORBENTS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 REVENUE $5.743 MILLION VERSUS I/B/E/S VIEW $5.8 MILLION.Q3 2018 TOTAL REVENUES WERE ABOUT $5.7 MILLION VERSUS $3.8 MILLION.EXPECT Q4 2018 PRODUCT SALES TO EXCEED Q3 2018 PRODUCT SALES.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up